NasdaqGS - Delayed Quote USD

Bruker Corporation (BRKR)

78.05 +0.29 (+0.37%)
At close: April 22 at 4:00 PM EDT
78.05 0.00 (0.00%)
After hours: April 22 at 4:06 PM EDT
Loading Chart for BRKR
DELL
  • Previous Close 77.76
  • Open 80.64
  • Bid 77.98 x 200
  • Ask 78.08 x 200
  • Day's Range 77.08 - 80.64
  • 52 Week Range 53.79 - 94.86
  • Volume 794,619
  • Avg. Volume 804,479
  • Market Cap (intraday) 11.343B
  • Beta (5Y Monthly) 1.18
  • PE Ratio (TTM) 26.91
  • EPS (TTM) 2.90
  • Earnings Date May 2, 2024 - May 6, 2024
  • Forward Dividend & Yield 0.20 (0.26%)
  • Ex-Dividend Date Feb 29, 2024
  • 1y Target Est 88.40

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

www.bruker.com

9,707

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BRKR

Performance Overview: BRKR

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BRKR
6.28%
S&P 500
5.05%

1-Year Return

BRKR
3.86%
S&P 500
21.22%

3-Year Return

BRKR
16.22%
S&P 500
20.06%

5-Year Return

BRKR
107.58%
S&P 500
72.48%

Compare To: BRKR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BRKR

Valuation Measures

Annual
As of 4/22/2024
  • Market Cap

    11.34B

  • Enterprise Value

    12.23B

  • Trailing P/E

    26.91

  • Forward P/E

    28.49

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.88

  • Price/Book (mrq)

    8.24

  • Enterprise Value/Revenue

    4.13

  • Enterprise Value/EBITDA

    18.11

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.41%

  • Return on Assets (ttm)

    7.70%

  • Return on Equity (ttm)

    33.67%

  • Revenue (ttm)

    2.96B

  • Net Income Avi to Common (ttm)

    427.2M

  • Diluted EPS (ttm)

    2.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    500.3M

  • Total Debt/Equity (mrq)

    95.72%

  • Levered Free Cash Flow (ttm)

    291.71M

Research Analysis: BRKR

Analyst Price Targets

73.03 Low
88.40 Average
78.05 Current
105.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: BRKR

Fair Value

78.05 Current
 

Dividend Score

0 Low
BRKR
Sector Avg.
100 High
 

Hiring Score

0 Low
BRKR
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
BRKR
Sector Avg.
100 High
 

Research Reports: BRKR

  • BRKR: Lowering target price to $74.00

    BRUKER CORP has an Investment Rating of SELL; a target price of $74.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • BRKR: What does Argus have to say about BRKR?

    BRUKER CORP has an Investment Rating of SELL; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • BRKR: Lowering target price to $75.00

    BRUKER CORP has an Investment Rating of SELL; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • BRKR: Lowering target price to $76.00

    BRUKER CORP has an Investment Rating of SELL; a target price of $76.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch